Over at Pacific Standard, I offer brief layman’s guide to the latest pluripotent stem cell technologies, and I argue that better stem cell technology will not make the ethical controversy go away. (In last week’s Nature, Martin Pera & Alan Trounson make a similar point.)
To understand where I’m coming from, let’s take a step back a few years, in the aftermath of the Bush Administration’s controversial decision to limit NIH-funded research on human embryonic stem cell (ESC) lines. Back then, much of the debate was over the merits and ethics of ESC’s versus lineage-restricted adult stem cells: ESCs were for the most part derived from leftover IVF embryos or aborted fetuses (and thus didn’t carry the genome of a patient). Adult stem cells could be taken from patients, but were much more restricted in their potential applications. Dolly the sheep was old news at that point, but the technology to create Dolly (and thus also create embryonic stem cells with the genome of a living adult) did not actually work with human cells. Continue reading “Better stem cell tech, more controversy”